Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ADX-097 · 1 trial · 3 indications
| Arm | Type | Description |
|---|---|---|
| Open Label: ADX-097 | OTHER | Participants will be administered ADX-097 weekly once |
| Name | Type | Description |
|---|---|---|
| ADX-097 | DRUG | Subcutaneous Infusions |
Key Inclusion Criteria: All participants 1. Male or female participants aged ≥16 years. 2. uPCR ≥0.5 g/g (from the average of 3 first morning voids \[FMVs\]). 3. Screening eGFR ≥30 mL/min/1.73m2 calculated by the Chronic Kidney Disease Epidemiology Collaboration creatinine equation (CKD-EPI GFR). ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Novartis AG Sponsored ADR | NVS | 10 | PHASE3 | BION-1301 |
| Vera Therapeutics, Inc. Class A | VERA | 4 | PHASE3 | Atacicept |
| Travere Therapeutics, Inc. | TVTX | 2 | PHASE3 | sparsentan, irbesartan, Dapagliflozin |
| Biogen Inc. | BIIB | 1 | PHASE3 | Felzartamab |
| AstraZeneca PLC | AZN | 2 | PHASE3 | Ravulizumab |
| Vertex Pharmaceuticals Incorporated | VRTX | 2 | PHASE3 | Povetacicept |
| Biohaven Ltd. | BHVN | 1 | PHASE1 | BHV-1400 |
| Jade Biosciences, Inc. | JBIO | 1 | PHASE2 | JADE101 |
| Q32 Bio Inc | QTTB | 1 | PHASE2 | ADX-097 |
ADX-097 is an investigational small molecule being developed for IgA Nephropathy, a kidney disease. It is also being studied for Lupus Nephritis and C3 Glomerulopathy. The drug is currently in Phase 2 clinical development and has not been approved by regulatory authorities.
ADX-097 is being developed by Q32 Bio Inc., a biopharmaceutical company. The company's stock is traded under the ticker QTTB. Q32 Bio is conducting clinical trials to evaluate the safety and activity of ADX-097 in patients with kidney diseases.
ADX-097 is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by regulatory agencies. The drug is currently being studied in a Phase 2 trial to evaluate its safety, pharmacokinetics, pharmacodynamics, and clinical activity in patients.
ADX-097 is being studied in a Phase 2 clinical trial with the identifier NCT06419205. This trial is recruiting participants with IgA Nephropathy, Lupus Nephritis, or C3 Glomerulopathy. The study is being conducted in the United States and Brazil and aims to enroll 30 participants.
ADX-097 is the primary name for this investigational drug. No alternative names have been reported. It is a small molecule being developed by Q32 Bio Inc. for the treatment of kidney diseases, including IgA Nephropathy.